Phase 3 Readout~month

Phase 3 Topline: A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial I

Indication
Early Alzheimers Disease

Other upcoming events for ANVS

Phase 3 ReadoutPhase 3 Topline: An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participan

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial I — ANVS Phase 3 Readout | BioSniper